Fusion Antibodies
Pre-clinical antibody discovery, engineering, and supply services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 97.5x EV/EBITDA | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | £1.2m | Post IPO Equity |
| Total Funding | 000k | ||
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 7 % | 15 % | (40 %) | (61 %) | 73 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (11 %) | (13 %) | (12 %) | (86 %) | (182 %) | (71 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (18 %) | (70 %) | (25 %) | (89 %) | (196 %) | (75 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Fusion Antibodies plc is a collaborative research organization (CRO) that provides a range of antibody engineering services for developing therapeutic drugs and diagnostic applications. The company was established in 2001 as a spin-out from Queen's University Belfast. Initially a drug development business, it shifted its focus to CRO services in 2011.
The company's services cover the entire antibody development process, from discovery and engineering to the supply of pre-clinical biologics and clinical cell line development. Key offerings include antibody sequencing, humanization through its proprietary CDRx™ platform, affinity maturation (RAMP®), protein engineering, monoclonal antibody production, and stable cell line development. Fusion Antibodies serves an international client base that includes eight of the top ten global pharmaceutical companies. Its business model operates as a fee-for-service CRO, generating revenue by providing these specialized services to biopharmaceutical and diagnostic companies.
A significant milestone in the company's history was its debut on the AIM of the London Stock Exchange in December 2017, raising £5.5 million. This funding was aimed at expanding laboratory space, increasing sales and marketing efforts, and developing new service lines. Dr. Paul Kerr, the CEO at the time of the IPO, has a background of over 20 years in the biotechnology sector and is an alumnus of Queen's University Belfast. As of August 2022, Dr. Adrian Kinkaid, an executive with 25 years of experience in the life sciences and biotherapeutics industries, serves as the CEO. The company is also developing new technology platforms, such as OptiMAL®, a mammalian antibody library for discovery, which recently received a patent issue notification from the U.S. Patent Office.
Keywords: collaborative research organization, antibody engineering, antibody humanization, cell line development, therapeutic drug discovery, diagnostic applications, preclinical biologics, protein engineering, monoclonal antibody production, CDRx platform, RAMP platform, OptiMAL library, biopharmaceutical services, antibody sequencing, affinity maturation, pre-clinical CRO, antibody development, antibody discovery, recombinant proteins, biologics manufacturing